A Swiss microbiota biotherapeutics and mucosal vaccines company with two technology platforms: ApyraVax for the generation of innovative mucosal vaccines; ApyraMed with indications in IBD, dysbiosis induced by antibiotic treatments and unhealthy diet, and as enhancer in cancer immunotherapy.
- https://www.mv-bio.com/
- +41 79 214 35 82
- Send an email
- Fabio Grassi